Literature DB >> 19806287

Diagnosis and referral of rheumatoid arthritis by primary care physician: results of a pilot study on the city of Pisa, Italy.

Alessandra Della Rossa1, Rossella Neri, Rosaria Talarico, Marica Doveri, Arianna Consensi, Stefano Salvadori, Valentina Lorenzoni, Giuseppe Turchetti, Stefania Bellelli, Massimiliano Cazzato, Laura Bazzichi, Paolo Monicelli, Stefano Moscardini, Stefano Bombardieri.   

Abstract

The aims of the present study were to evaluate, in the city of Pisa: (1) the prevalence of rheumatoid arthritis; (2) the reliability of the prevalence estimated by primary care physicians, using the rheumatologist's diagnosis as the "gold standard" and (3) the economic impact of the disease. The Tuscany registry of primary care physicians constituted the framework from which a sample of subjects was selected. The rheumatoid arthritis (RA) subjects >18 years followed by each primary care physician constituted the population studied. Each general practitioner (GP) was asked to fill out a questionnaire regarding their patients affected by RA and to send it to the tertiary rheumatologic centre, where the diagnosis was confirmed/discarded, the clinical and epidemiological data were collected in a standardized form and a number of data for the estimation of costs were gathered. The estimated prevalence of RA was 5.1 per thousand (CI, 4.4-5.7). The reliability of general practitioners in the diagnosis of rheumatoid arthritis was on the whole 69%. However, when an analysis of every physician was carried out, a high degree of heterogeneity in the prevalence of RA per physician was found. Overall, the mean annual cost per patient with RA was estimated at about 5,878 euro (euro; median, 6,434 euro; inter quartile range, 669-7,052 euro), with a high variability mainly dependent on the degree of patient disability. More than 90% of the overall annual cost per patient was due to the medical and non-medical direct components of costs. The prevalence of RA in Tuscany seems highly comparable with similar prevalence studies in Italy. The annual cost per patient with RA was highly variable and strictly dependent on the level of disability. More than 90% of the overall cost was due to the direct burden of costs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19806287     DOI: 10.1007/s10067-009-1285-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  40 in total

1.  Prevalence of rheumatoid arthritis in Dublin, Ireland: a population based survey.

Authors:  D Power; M Codd; L Ivers; S Sant; M Barry
Journal:  Ir J Med Sci       Date:  1999 Jul-Sep       Impact factor: 1.568

2.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

3.  The prevalence of rheumatoid arthritis in the general population of Spain.

Authors:  L Carmona; V Villaverde; C Hernández-García; J Ballina; R Gabriel; A Laffon
Journal:  Rheumatology (Oxford)       Date:  2002-01       Impact factor: 7.580

4.  The prevalence of rheumatoid arthritis in Sweden.

Authors:  M Simonsson; S Bergman; L T Jacobsson; I F Petersson; B Svensson
Journal:  Scand J Rheumatol       Date:  1999       Impact factor: 3.641

5.  The use of databases for quality assessment in rheumatoid arthritis.

Authors:  T A Stamm; D Aletaha; S Pflugbeil; T Kapral; K Montag; K P Machold; J S Smolen
Journal:  Clin Exp Rheumatol       Date:  2007 Nov-Dec       Impact factor: 4.473

6.  Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUEST-RA global perspective.

Authors:  T Sokka; G Haugeberg; T Pincus
Journal:  Clin Exp Rheumatol       Date:  2007 Nov-Dec       Impact factor: 4.473

Review 7.  Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.

Authors:  Nick Bansback; Roberta Ara; Jonathan Karnon; Aslam Anis
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Low prevalence of rheumatoid arthritis in the urbanized Chinese of Hong Kong.

Authors:  E Lau; D Symmons; C Bankhead; A MacGregor; S Donnan; A Silman
Journal:  J Rheumatol       Date:  1993-07       Impact factor: 4.666

9.  Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy.

Authors:  E G Favalli; A Marchesoni; G L Colombo; L Sinigaglia
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

Review 10.  Epidemiology and genetics of rheumatoid arthritis.

Authors:  Alan J Silman; Jacqueline E Pearson
Journal:  Arthritis Res       Date:  2002-05-09
View more
  10 in total

1.  Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.

Authors:  Francesco Saverio Mennini; Andrea Marcellusi; Lara Gitto; Florenzo Iannone
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

2.  The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review.

Authors:  Khalid Almutairi; Johannes Nossent; David Preen; Helen Keen; Charles Inderjeeth
Journal:  Rheumatol Int       Date:  2020-11-11       Impact factor: 2.631

Review 3.  Patterns of disease-modifying antirheumatic drug use in rheumatoid arthritis patients after 2002: a systematic review.

Authors:  Gabriela Schmajuk; Daniel H Solomon; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-12       Impact factor: 4.794

4.  The descriptive epidemiology of rheumatoid arthritis in Catalonia: a retrospective study using routinely collected data.

Authors:  F Fina-Aviles; M Medina-Peralta; L Mendez-Boo; E Hermosilla; J M Elorza; M Garcia-Gil; R Ramos; B Bolibar; M K Javaid; C J Edwards; C Cooper; N K Arden; D Prieto-Alhambra
Journal:  Clin Rheumatol       Date:  2014-10-26       Impact factor: 2.980

5.  Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature.

Authors:  Maurizio Benucci; Gianantonio Saviola; Mariangela Manfredi; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  Int J Rheumatol       Date:  2011-11-22

6.  Estimating the prevalence and disease characteristics of rheumatoid arthritis in Tehran: A WHO -ILAR COPCORD Study (from Iran COPCORD study, Urban Study stage 1).

Authors:  Ahmad-Reza Jamshidi; Arash Tehrani Banihashemi; Shima Roknsharifi; Masoumeh Akhlaghi; Ahmad Salimzadeh; Fereydoun Davatchi
Journal:  Med J Islam Repub Iran       Date:  2014-09-14

7.  A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology.

Authors:  Greta Carrara; Carlo A Scirè; Antonella Zambon; Marco A Cimmino; Carlo Cerra; Marta Caprioli; Giovanni Cagnotto; Federica Nicotra; Andrea Arfè; Simona Migliazza; Giovanni Corrao; Giovanni Minisola; Carlomaurizio Montecucco
Journal:  BMJ Open       Date:  2015-01-28       Impact factor: 2.692

Review 8.  Costs associated with rheumatoid arthritis in Italy: past, present, and future.

Authors:  Maurizio Benucci; Veronica Rogai; Fabiola Atzeni; Volker Hammen; Piercarlo Sarzti-Puttini; Alberto Migliore
Journal:  Clinicoecon Outcomes Res       Date:  2016-02-10

9.  Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.

Authors:  Maria Lucia Specchia; Chiara de Waure; Maria Rosaria Gualano; Andrea Doria; Giuseppe Turchetti; Lara Pippo; Francesco Di Nardo; Silvio Capizzi; Chiara Cadeddu; Flavia Kheiraoui; Luca Iaccarino; Francesca Pierotti; Ilaria Palla; Maria Assunta Veneziano; Daniela Gliubizzi; Antonella Sferrazza; Nicola Nicolotti; Rolando Porcasi; Giuseppe La Torre; Maria Luisa Di Pietro; Walter Ricciardi
Journal:  Biomed Res Int       Date:  2014-08-17       Impact factor: 3.411

Review 10.  Rare diseases under different levels of economic analysis: current activities, challenges and perspectives.

Authors:  Sara Cannizzo; Valentina Lorenzoni; Ilaria Palla; Salvatore Pirri; Leopoldo Trieste; Isotta Triulzi; Giuseppe Turchetti
Journal:  RMD Open       Date:  2018-11-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.